Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants on December 15, 2026. There are 6 upcoming events on record.
Cash runway is approximately 23.3 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 7 concluded trials, 100% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| December 15, 2026 | First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants | Trial Milestone | Phase 1 |
| December 23, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| April 15, 2027 | A Study to Evaluate Different Oral Formulations of KT-621 | Trial Milestone | Phase 1 |
| June 15, 2027 | A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis | Trial Milestone | Phase 2 |
| December 15, 2027 | A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma | Trial Milestone | Phase 2 |
| December 15, 2028 | A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study | Trial Milestone | Phase 2 |
Track KYMR alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open KYMR in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.